Senna Benefits

Senna (Senna alexandrina Mill., family Fabaceae — also catalogued as Cassia senna, Cassia angustifolia and Cassia acutifolia) is one of a very small number of plants on this site that is not a candidate remedy awaiting better evidence. It is a licensed medicine. In the United States it sits in the Food and Drug Administration’s over-the-counter monograph for laxative drug products; in the United Kingdom and across the European Union it holds full marketing authorisations and traditional-use registrations; it is on the World Health Organization’s list of essential medicines. You can buy it in a pharmacy as sennoside tablets, and it is widely used alongside opioid painkillers in palliative care.

So the interesting question about senna is not “does it work.” It does. Placebo-controlled trials have measured the effect, and it is not subtle. The interesting question is the one almost no marketing copy answers: what is it for, for how long, and what happens to people who ignore that. Senna’s harms are almost entirely harms of duration and context. A dose taken tonight for a blocked-up week of travel is an ordinary, sensible use of an ordinary, sensible drug. The same dose taken every night for two years, or brewed into a “14-day detox” tea and drunk for weight control, is how people end up in an emergency department with a potassium of 2.4.

These four articles cover both halves honestly: the real pharmacology and the real trial data, and then the real risks — electrolyte loss, the pigmented colon lining called melanosis coli, the long-running argument about whether chronic use produces a “cathartic colon,” and the slimming-tea market where most of the genuine harm actually occurs.

Table of Contents

  1. Deep-Dive Articles
  2. What Senna Is and What It Is Licensed For
  3. The Standard Dose, in One Table
  4. Not the Same Plant as Senna alata
  5. Where the Evidence Is Strong — and Where It Is Not
  6. The One-Week Limit, and Why It Exists
  7. Key Research Papers
  8. External Resources
  9. Connections
  10. Featured Videos

Deep-Dive Articles

Short-term use is the licensed indication and the one supported by controlled trials. The long-term risk article covers what is known about taking it for months or years.

What Senna Is and What It Is Licensed For

Senna is a small, drought-tolerant shrub of the pea family that grows across the Nile valley, the Arabian peninsula, the Horn of Africa and India. Two commercial sources dominate: Alexandrian senna, historically shipped from Egypt and Sudan, and Tinnevelly senna, grown in southern India. Both are now treated as the single species Senna alexandrina. Two plant parts are used:

The regulatory position is unusually clear for a botanical. Senna appears in the US FDA over-the-counter (OTC) monograph for stimulant laxatives, meaning products can be sold as drugs with approved labelling rather than as dietary supplements. In the European Union, the Committee on Herbal Medicinal Products has issued monographs for both leaf and pod covering short-term use in occasional constipation. The World Health Organization includes senna in its Model List of Essential Medicines. The German Commission E approved it decades ago. This is not a plant that needs anyone’s advocacy.

Those authorisations limit senna to occasional constipation and to short use. The US over-the-counter label reads: “Do not use laxative products for longer than 1 week unless directed by a doctor.” The European Union monograph for senna leaf says it is “not to be used for more than 1 week.” That restriction is part of the licence, not a disclaimer bolted on by a cautious lawyer.

The Standard Dose, in One Table

Modern senna products are standardised to sennosides, usually expressed as sennoside B. This matters more than any other label feature: crude leaf varies severalfold in potency between harvests, but a tablet labelled “8.6 mg sennosides” delivers 8.6 mg.

QuestionStandard answerNote
Adult doseEuropean Union monograph: 10–30 mg sennosides once daily at night, for people over 12The US label for 8.6 mg tablets (adults and children 12 and over) gives a starting dose of 2 tablets once a day. The European monograph describes the right dose as the smallest that produces a comfortable soft motion.
When to take itAt bedtimeOnset is 6–12 hours, so a bedtime dose gives a morning result.
Maximum in the labelUS label (8.6 mg tablets, adults and children 12 and over): 4 tablets twice a dayThe European monograph gives a single dose once daily. Doubling the dose mostly doubles the cramping.
How longUp to 1 weekUS label: “Do not use laxative products for longer than 1 week unless directed by a doctor.” The European monograph also says not more than 1 week.
ChildrenUS label: ages 6 to under 12, 1 tablet once a day (maximum 2 tablets twice a day); ages 2 to under 6, ½ tablet once a day (maximum 1 tablet twice a day); under 2, “ask a doctor”The European Union monograph lists use in children under 12 as a contraindication.
PregnancyThe European Union monograph lists pregnancy and breastfeeding as contraindicationsIt cites animal data on a genotoxic risk from some anthranoids, and rhein passing into breast milk in small amounts. The US label reads: “If pregnant or breast-feeding, ask a health professional before use.”
TeaHard to doseSteep time changes the dose. A long brew can be several times a tablet.

The single most common self-inflicted injury with senna is not overdose in milligrams — it is overdose in weeks.

Not the Same Plant as Senna alata

The genus Senna contains more than 300 species and two of them are widely used medicinally for completely different purposes. Confusing them is common in online writing and occasionally in product labelling.

Senna alexandrina — this pageSenna alata — a different plant
Common namesSenna, Alexandrian senna, Tinnevelly sennaRingworm bush, candle bush, Cassia alata, akapulko
Part usedLeaf and podLeaf, usually fresh
Main useOral laxativeTopical antifungal for ringworm and related skin infections
RouteSwallowedApplied to the skin as a poultice, decoction or cream
Best evidencePlacebo-controlled laxative trials; licensed over-the-counter drugSmall clinical work in tinea, plus antifungal laboratory data

They share the anthraquinone chemistry of the genus, which is why S. alata leaf also has a laxative effect if eaten in quantity — but its documented use is on the skin, not in the gut. Our separate page on Cassia alata (Ringworm Bush) covers that species. If a product says “senna” and shows a picture of a bright yellow candle-shaped flower spike, it is alata, not alexandrina.

Where the Evidence Is Strong — and Where It Is Not

UseBest available evidenceHonest verdict
Occasional constipationRandomised, placebo-controlled trial data plus pooled analyses of stimulant laxativesEstablished. This is the licensed indication and it holds up. In a 2021 placebo-controlled trial of 90 people over 28 days, 69.2% improved overall on senna 1.0 g, against 11.7% on placebo and 68.3% on magnesium oxide, with no severe treatment-related side effects.
Opioid-induced constipationRandomised comparisons against lactulose and lubiprostone; Cochrane review of palliative-care laxativesEstablished as a reasonable first-line option, though the palliative-care trials are small and the review found no clear winner among laxatives.
Constipation in older adultsRandomised trials of senna-fibre combinations versus lactulose in long-stay elderly patientsSupported, with senna-fibre outperforming lactulose on stool frequency in the trials that tested it.
Paediatric constipationCochrane review of osmotic and stimulant laxatives; small surgical-population trialsUsed in practice, evidence thin. Polyethylene glycol is better studied. The US label gives over-the-counter doses from age 2; the European Union monograph lists children under 12 as a contraindication.
Bowel preparation before colonoscopyA 2022 meta-analysis of 11 trials (3,343 patients)A supervised, one-off, high-dose use. Senna regimens cleaned the bowel about as well as other regimens (odds ratio 1.02, no significant difference), with better tolerance and compliance and less nausea.
Weight lossMetabolic-ward measurement of calorie loss from purging; eating-disorder literatureDoes not work. The weight lost is water and stool. See the detox-tea article.
“Detox” or “cleansing”NoneNo mechanism, no evidence. Emptying the colon does not remove toxins from tissue.

The 2023 joint guideline of the American Gastroenterological Association and the American College of Gastroenterology on long-term (chronic idiopathic) constipation in adults made a conditional recommendation for senna, alongside fibre, lactulose, magnesium oxide and lubiprostone. It made strong recommendations for polyethylene glycol, sodium picosulfate, linaclotide, plecanatide and prucalopride.

The One-Week Limit, and Why It Exists

Every regulator that has looked at senna landed on roughly the same duration limit. It is worth understanding what that limit is actually protecting against, because the popular explanation is only partly right.

  1. Electrolyte loss is the real hazard. Stimulant laxatives make the colon secrete fluid. Do that repeatedly and you lose water, sodium and — most importantly — potassium. Low potassium causes muscle weakness, cramps and, in the wrong patient, dangerous heart rhythms. It is also directly dangerous alongside potassium-lowering drugs: digoxin becomes more toxic when potassium falls, and thiazide or loop diuretics add their own losses to senna’s.
  2. Low potassium makes constipation worse. Potassium is needed for smooth-muscle contraction. Lose enough and the colon slows down — which feels exactly like the laxative “stopping working,” and invites a larger dose. That loop is the mechanism behind most escalating laxative use, and it is far better documented than nerve damage.
  3. The colon does change colour. Months of anthraquinone use deposits brown-black pigment in the lining, a finding called melanosis coli. It is startling on a colonoscopy report, and it fades within months of stopping. Whether it signals any cancer risk is mixed: a prospective case-control study found no significant link between anthranoid use or melanosis coli and colorectal adenomas or cancer, while a 1999 review noted that pseudomelanosis coli had been associated with a higher risk of colorectal cancer, and a 2022 Japanese colonoscopy study found more adenomas in people with severe melanosis coli, which was more common among anthranoid users.
  4. Whether the colon is permanently damaged is genuinely unsettled. The old “cathartic colon” picture came from radiology and autopsy studies in an era of much harsher laxatives. Some rodent work found neuronal changes; other work specifically testing sennosides found no myenteric neuron death. Reviews since the 1990s have argued the dependence story is largely unsupported — a 2005 review of constipation myths concluded that tolerance to stimulant laxatives is uncommon, that there is no sign of “rebound constipation” after stopping, and that laxatives carry no potential for addiction; a 2024 critical review revisited the whole question and found the evidence for gut damage weak. The honest position is that nobody has run the trial that would settle it, so the one-week limit is precaution, not proof.
  5. Persistent constipation is a symptom, not a diagnosis. When a laxative is still needed after a week, the useful question is why — hypothyroidism, medication side effects, pelvic floor dysfunction, low fibre, diabetes, or something that needs looking at. Escalating the dose answers none of those.

The most severe case in this page’s sources shows what dose and duration can do. A 52-year-old woman who drank one litre a day of tea made from 70 g of dried senna pods for more than three years developed acute liver failure (her clotting test, the international normalised ratio, rose above 7) and kidney damage, and needed intensive care. She recovered with supportive treatment; the authors rated senna as a “possible” cause.

Key Research Papers

Every identifier below was checked live against NCBI E-utilities before it was written: author, title, journal and year all had to match. Where a paper could not be confirmed that way, a PubMed topic search appears instead of a number that might point at the wrong study.

Efficacy in constipation

  1. Morishita D, Tomita T, Mori S, et al. Senna versus magnesium oxide for the treatment of chronic constipation: a randomized, placebo-controlled trial. The American Journal of Gastroenterology. 2021;116(1):152–161 — PubMed PMID: 32969946 — The most useful modern trial: senna beat placebo, and was compared head-to-head with magnesium oxide.
  2. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60(2):209–218. — PubMed PMID: 21205879
  3. Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. The American Journal of Gastroenterology. 2005;100(4):936–971. — PubMed PMID: 15784043
  4. Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023;164(7):1086–1106. — PubMed PMID: 37211380
  5. Tian H, Fan Y, Yang L, et al. The efficacy of senna bowel preparation for colonoscopy: a systematic review and meta-analysis. Gastroenterology Nursing. 2022;45(6):428–439. — PubMed PMID: 35758925
  6. Passmore AP, Wilson-Davies K, Stoker C, Scott ME. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ. 1993;307(6907):769–771. — PubMed PMID: 8219947

Opioid-induced constipation and palliative care

  1. Agra Y, Sacristán A, González M, Ferrari M, Portugués A, Calvo MJ. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. Journal of Pain and Symptom Management. 1998;15(1):1–7. — PubMed PMID: 9436336
  2. Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database of Systematic Reviews. 2015;(5):CD003448 — PubMed PMID: 25967924 — Found the evidence base small and no laxative clearly superior — an honest negative for anyone claiming senna is proven best here.
  3. Marciniak CM, Toledo S, Lee J, et al. Lubiprostone vs senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial. World Journal of Gastroenterology. 2014;20(43):16323–16333. — PubMed PMID: 25473191

Mechanism and pharmacokinetics

  1. de Witte P. Metabolism and pharmacokinetics of anthranoids. Pharmacology. 1993;47(Suppl 1):86–97. — PubMed PMID: 8234447
  2. Akao T, Che QM, Kobashi K, Yang L, Hattori M, Namba T. Isolation of a human intestinal anaerobe, Bifidobacterium sp. strain SEN, capable of hydrolyzing sennosides to sennidins. Applied and Environmental Microbiology. 1994;60(3):1041–1043. — PubMed PMID: 8161172
  3. Krumbiegel G, Schulz HU. Rhein and aloe-emodin kinetics from senna laxatives in man. Pharmacology. 1993;47(Suppl 1):120–124. — PubMed PMID: 8234418

Long-term safety, melanosis coli and the cathartic-colon debate

  1. Whorwell P, Lange R, Scarpignato C. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. Therapeutic Advances in Gastroenterology. 2024;17:17562848241249664. — PubMed PMID: 38887508
  2. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. The American Journal of Gastroenterology. 2005;100(1):232–242. — PubMed PMID: 15654804
  3. Nusko G, Schneider B, Schneider I, Wittekind C, Hahn EG. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut. 2000;46(5):651–655. — PubMed PMID: 10764708
  4. van Gorkom BA, de Vries EG, Karrenbeld A, Kleibeuker JH. Review article: anthranoid laxatives and their potential carcinogenic effects. Alimentary Pharmacology & Therapeutics. 1999;13(4):443–452. — PubMed PMID: 10215727
  5. Katsumata R, Manabe N, Monobe Y, et al. Severe grade of melanosis coli is associated with a higher detection rate of colorectal adenoma. Journal of Clinical Biochemistry and Nutrition. 2022;71(2):165–171. — PubMed PMID: 36213792
  6. Walker NI, Bennett RE, Axelsen RA. Melanosis coli: a consequence of anthraquinone-induced apoptosis of colonic epithelial cells. The American Journal of Pathology. 1988;131(3):465–476. — PubMed PMID: 3381879

Misuse, weight control and eating disorders

  1. Bo-Linn GW, Santa Ana CA, Morawski SG, Fordtran JS. Purging and calorie absorption in bulimic patients and normal women. Annals of Internal Medicine. 1983;99(1):14–17 — PubMed PMID: 6190422 — The metabolic-ward study that measured how few calories purging actually removes.
  2. Roerig JL, Steffen KJ, Mitchell JE, Zunker C. Laxative abuse: epidemiology, diagnosis and management. Drugs. 2010;70(12):1487–1503. — PubMed PMID: 20687617
  3. Vanderperren B, Rizzo M, Angenot L, Haufroid V, Jadoul M, Hantson P. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. The Annals of Pharmacotherapy. 2005;39(7–8):1353–1357. — PubMed PMID: 15956233

PubMed Topic Searches

  1. PubMed: Senna alexandrina
  2. PubMed: Sennosides and constipation
  3. PubMed: Rhein anthrone
  4. PubMed: Melanosis coli
  5. PubMed: Cathartic colon
  6. PubMed: Laxative abuse and hypokalaemia
  7. PubMed: Opioid-induced constipation and senna
  8. PubMed: Anthranoid laxatives and colorectal neoplasia

External Resources

Connections


Back to Table of Contents